




## **SUPPLEMENTAL MATERIAL**




**Online Figure I.  $\text{Ca}^{2+}$  binding affinity plot of RGECO, RGECO-TnT and RGECO-TnI.** The steady state  $\text{Ca}^{2+}$  binding affinity of purified recombinant RGECO (red lines) RGECO-TnT (purple lines) and RGECO-TnI (blue lines) was assessed by analysis of the fluorescence/pCa relationship at 37 °C, 1.3 mM  $\text{MgCl}_2$  and pH 7.3 (n=4).




**Online Figure II. Kinetic determination of  $k_{\text{on}}$  and  $k_{\text{off}}$  for RGECHO-TnT by stopped flow.** Arrhenius plots of the observed rate constant of  $\text{Ca}^{2+}$  binding (A) and  $\text{Ca}^{2+}$  release rate constant (B) as determined by stopped flow measurement of 0.125  $\mu\text{M}$  purified RGECHO-TnT protein. Data for room (25  $^{\circ}\text{C}$ ) and body (37  $^{\circ}\text{C}$ ) temperature are shown in (C).



**Online Figure III. Contractile properties of RGECO, RGECO-TnT and RGECO-TnI.** Contractile parameters during electrical paced (0.5 Hz) of isolated adult cardiomyocytes transduced and either RGECO, RGECO-TnT or RGECO-TnI showing no change in basal sarcomere length (A), time to 50% contraction (B) or time to 50% relaxation (C) (n=33-64 cells from n=3 isolations).




**Online Figure IV. Subcellular fractionation of GPCMs expressing RGECO-TnT and RGECO-TnI.** The relative subcellular incorporation of RGECO-TnT or RGECO-TnI was assessed by subcellular fractionation of GPCMs 48 hours after adenoviral infection. Western blots using anti-cTnT or anti-cTnI gave an endogenous band and a conjugate band on the sarcomeric fraction (sarc) (**A**). Re-probing with the predominantly cytoplasmic marker anti-ERK showed that subcellular fractionation was of high fidelity (**B**).




	Fluo-4	RGECO-TnT
$T_{50}$ on (sec)	$0.059 \pm 0.003$	$0.088 \pm 0.004^*$
$T_{50}$ off (sec)	$0.418 \pm 0.026$	$0.316 \pm 0.038^*$

**Online Figure V. The on and off rates of  $\text{Ca}^{2+}$  transients measured with Fluo-4 are significantly different to RGECO-TnT in simultaneous measurements if dye and sensor in the same cell.** Fluorescence measurements taken from cells loaded with  $0.5 \mu\text{mol/L}$  Fluo-4 and expressing RGECO-TnT were measured at  $488 \text{ nm}$  and  $595 \text{ nm}$  respectively. Emitted transients were from the same cell and therefore enabled direct pairwise comparison of  $T_{50}$  on and  $T_{50}$  off rates ( $n=82$  cells from  $n=3$  isolations). Data presented as mean  $\pm$  SEM, \* =  $p < 0.05$ , using Wilcoxon paired t-test.



**Online Figure VI. RGECHO, RGECHO-TnT and RGECHO-TnI  $\text{Ca}^{2+}$  transients show reverse rate dependence in times to 50% on and 50% off in response to increased pacing frequency in adult GPCMs.** Averaged  $\text{Ca}^{2+}$  transients of electrically paced isolated adult cardiomyocytes was used to compare pacing frequencies of 0.5 Hz, 1.0 Hz and 2 Hz using either RGECHO (A), RGECHO-TnT (D) or RGECHO-TnI (G). Adjacent dot plots show distributions of time to 50% binding, and 50% release rates across the pacing range. Shortening of both parameters is apparent for all indicators (RGECHO (B and C) (n=21 cells from n=2 isolations), RGECHO-TnT (E and F) (n=24 cells from n=2 isolations), and RGECHO-TnI (H and I) (n=56 cells from n=3 isolations)). Lines give the median average and error bars are  $\pm$  interquartile range \* =  $p < 0.05$ , \*\* =  $p < 0.01$  and \*\*\* =  $p < 0.001$  using one way ANOVA.




**Online Figure VII. MYK-461 and levosimendan had no direct effect on the function of the RGECHO-TnT.**

Fluorescence : pCa relationship in the presence of 250 nmol/L MYK-461 and 10  $\mu$ mol/L levosimendan was used to calculate the  $K_d$  values tabulated beneath ( $n=4$ ). Significance values ( $p$ ) were calculated using one way ANOVA.


### Cytoplasmic RGECO

**A**




### Myofilament RGECO

**B**



**Online Figure VIII. Effect of dual transduction versus single transduction of adenoviruses on FLAG-tag expression.** Western blot analysis of GPCMs transduced with WT cTnT, cTnT R92Q, WT cTnI, or cTnI R145G ± RGECHO (A) or RGECHO-TnI/RGECHO-TnT (B), or uninfected control (UI). Showing no significant effect on FLAG-tag expression between dual transduction with the  $\text{Ca}^{2+}$  sensor and single transduction without the  $\text{Ca}^{2+}$  sensor, n=5.



**Online Figure IX. Effect of dual transduction on the localisation of FLAG-tag expressed protein.**

Immunofluorescence analysis of GPCMs transduced with WT cTnT, cTnT R92Q, WT cTnI, or cTnI R145G ± RGECHO/RGECHO-TnI/RGECHO-TnT was performed using anti-FLAG tag (green) and anti-DsRed antibodies. No significant alterations to the I band localisation of FLAG-tag protein was observed between dual transduction with the  $\text{Ca}^{2+}$  sensor and previously described single transduction without the  $\text{Ca}^{2+}$  sensor.

## RGECO-TnT DNA sequence

ATGGTAGACTCATCACGTGTAAGTGGAAATAAGGCAGGTACGCAGTCAGAGCTATAGGTCGGCTGAGCTACCCGTGGTT  
TCCGAGCGGATGTACCCCGAGGACGGGCCCTCAAGAGCGAGATCAAGAAGGGCTGAGGCTGAAGGACGGCGGCCACTAC  
GCCGCCGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCCTGAGCTGCCGGCGCCTACATCGTAGACATCAAGTGGAC  
ATCGTGTCCCACAACGAGGACTACACCATCGTGAACAGTGCAGCAGCGCCGAGGGCCACTCCACCGCGGCATGGAC  
GAGCTATAACAAGGGAGGTACAGGCAGGACTCGTGAACAGGCCACGAGCTCGAGATCGAGGGCGAGGGCGAGGGCCCTACGAG  
GCCTTCAGACCGCTAACGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTCGCCTGGGACATCCTGTCCCCTCAGTCATG  
TACGGCTCCAAGGCCTACATTAAGCACCCAGCCGACATCCCCGACTACTTCAAGCTGTCTCCCGAGGGCTCAGGTGG  
GAGCGCTGATGAACTCGAGGACGGCGATTATTACGTTAACCAAGGACTCCTCCCTGAGGACGGCGTATTCACTAC  
AAGGTGAAGCTGCGCGCACCAACTTCCCCCGACGGCCCTGAATGCAGAAGAACCATGGCTGGGAGGCTACGCGT  
GACCAACTGACTGAGGAGCAGATCGCAGAATTAAAGAGGCTTCTCCCTATTGACAAGGACGGGATGGGACGATAACA  
ACCAAGGAGCTGGGACGGTGAATGCGGTCTCTGGGACAGAACCCACAGAAGCAGAGCTGAGGACATGATCAATGAAGTA  
GATGCGACGGTGACGGCACATTGACTTCCCTGAGTTCCTGACGATGGCAAGAAAATGAATGACACAGACAGTGA  
GAGGAAATTAGAGAAGCGTCCCGTGTGATAAGGACGGCAATGGCTACATCGCGCAGCAGAGCTCGCCACGTGATG  
ACAGACCTTGGAGAGAAGTTAACAGATGAGGAGGTTGATGAAATGATCAGGTAGCAGACATCGATGGGATGGTCAGGTA  
AACTACGAAGAGTTGTCAAATGATGACAGCGAAGGGATCCATGTCGACATAGAACAGGGTGGAAAGAGTACGAGGAG  
GAGGAGCAGGAAGAACGAGCTGTTGAAGAGCAGGAGGGCAGCGGAAGAGGATGCTGAAGCAGAGGCTGAGACCGAGGAG  
ACCAGGGCAGAAGAAGATGAAGAAGAACAGGAGGCTGAAGATGGCCAATGGAGGAGTCCAAACCAAGGCC  
AGGTGTTCATGCCCAACTGGTGCCTCCCAAGATCCCCGATGGAGAGAGACTGGACTTTGATGACATCCACCGGAAGGCC  
ATGGAGAAGGACCTGAATGAGTTGCAGGCGCTGATTGAGGCTCACTTGAGAACAGGAAGAACAGGAGGAGGAGCTCGTT  
TCTCTCAAAGACAGGATCGAGAGACGTCGGGAGCAGCGGGCGAGCAGCGCATCCGGATGAGCAGGGAGAAGGAGCG  
CAGAACCGCCTGGCTGAAGAGAGGGCTCGACGAGAGGAGGAGAACAGGAGGAAGGCTGAGGATGAGGCCCAGAACAG  
AAGGCTTGTCAAACATGATGCATTGGGGTACATCCAGAACAGGAGGAGGAGGAGGAGCTGGCATTGACCACCTGAATGAAGATCAGCTG  
ACTGAGCGGGAAAAGAAGAAGAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG  
AGGGAGAAGGCCAAGGAGCTGGCAGAGCATCTAACTGGAGGAGAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAG  
CAGAAATATGAGATCAATGTTCTCCGAAACAGGATCAACGATAACCAGAAAGTCTCCAAGAACCCGCGGGAGGCTAAAGTC  
ACCGGGCGCTGGAAATAG

## RGECO-TnT amino acid sequence

MVDSSRRKWNKAGHAVRAIGRLSSPVVSEMPEDGALKSEIKKGLRLKDGGHYAAEVKTTYKAKKPVQLPGAYIVDIKLD  
IVSHNEDYTIVEQCERAEGRHSTGGMDELYKGITGGSLVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGRPYE  
AFQTAKLKVTKGPLPFAWDILSPQFMYGSKAYIKHPADIPDYFKLSPPEGFRWERVMNFEDGGIIVVNQDSSLQDGFIY  
KVKLRTNFPPDPVMQKKTMGWEATRDQLTEEQIAEFKEAFSLFDKDGDTITKELGTVMRSLGQNPTAEALQDMINEV  
DADGDGTDFPEFLTMMARKMNDTDSEEEIREAFRVDKDGNGYIGAAELRHVMTDLGEKLTDEEVDEMIRVADIQDGQV  
NYEEFVQMMTAKGMSDIEEVVEEYEEEQEEAAEEDAEAAEATEETRAEEDEEEAEKAEDGPMEESKPKP  
RSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQALIEAHFENRKKEEEELVSLKDRIERRAERAEQQRIRNEREKER  
QNRLAEEARREEENRRKAEDEARKKKALSNMHFGGYIQKQAQTERKSGKRQTEREKKKILAERRKVLIAIDHLNEDQL  
REKAKELWQSISYLNLEAEKFQKQKYEINVLRNRINDNQVKSKTRGAKVTGRWK.

**Online Figure X. DNA and amino acid sequence of RGECO-TnT.** Sequence highlighted red is RGECO, purple is human cardiac TnT and black is a BamHI cloning site which corresponds to an additional GS linker sequence in the translated amino acid.

## RGECO-TnI DNA sequence

ATGGTAGACTCATCACGTGTAAGTGGATAAGGCAGGTACGCAGTCAGAGCTATAGGTGGCTGAGCTACCCGTGGTT  
TCCGAGCGGATGTACCCCGAGGACGGGCCCTCAAGAGCGAGATCAAGAAGGGGCTGAGGCTGAAGGACGGCGGCCACTAC  
GCCGCCGAGGTCAAGACCACCTACAAGGCCAAGAACGCCGTGCAGCTGCCGGCGCCTACATCGTAGACATCAAGTTGGAC  
ATCGTGTCCCACAACGAGGACTACACCATCGTGAACAGTGCACGCCGAGGGCCACTCCACCGCGGCATGGAC  
GAGCTATAACAAGGGAGGTACAGGCAGGTCTGGTGAGCAAGGGCAGGGAGGATAACATGCCATCATCAAGGAGTTCATG  
CGCTTCAGACCGCTAACGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTCGCCTGGGACATCCTGTCCCCTCAGTCATG  
TACGGCTCCAAGGCCTACATTAAGCACCCAGCCGACATCCCCGACTACTTCAAGCTGTCTCCCCGAGGGCTCAGGTGG  
GAGCGCTGATGAACTTCGAGGACGGCGCATTATTACGTTAACCAACAGGACTCCTCCCTGAGGACGGGTATTCATCTAC  
AAGGTGAAGCTGCGCGCACCAACTTCCCCCGACGGCCCTAATGCAGAAGAACCATGGCTGGGAGGCTACGCGT  
GACCAACTGACTGAGGAGCAGATCGCAGAATTAAAGAGGCTTCTCCCTATTGACAAGGACGGGATGGGACGATAACA  
ACCAAGGAGCTGGGACGGTGTGATGCGGTCTCTGGGAGAACCCACAGAAGCAGAGCTGAGGACATGATCAATGAAGTA  
GATGCGACGGTACGGCACATTGACTTCCCTGAGTCCCTGACGATGATGGCAAGAAAATGAATGACACAGACAGTGA  
GAGGAAATTAGAGAACGCTCCCGTGTGATAAGGACGGCAATGGCTACATCGCGCAGCAGGCTTCGCCACGTGATG  
ACAGACCTTGGAGAGAAGTTAACAGATGAGGAGGTTGATGAAATGATCAGGTAGCAGACATCGATGGGATGGTCAGGTA  
AACTACGAAGAGTTGTCAAATGATGACAGCGAAGCTCGAGATGGGGATGGGAGCAGCGATGCGGTAGGGCTAGGGAACCTCGC  
CCTGCACCAGCCCCAATCAGACGCCCTCCCAACTACCGCGTTATGCCACGGAGCCACGCCAAGAAAATCTAAG  
ATCTCCGCTCTAGAAAATTGCGACTGAGACTCTGCTGCTGAGATTGCAAAGCAAGAGCTGGAGCAGAGGGGGAG  
CGGCCGGAGAGAACGGGGCGCCTGAGCACCCGCTGCCAGCCGCTGGAGTTGACCGGGCTGGCTTCGCGGAGCTGCAG  
GACTTGTGCCACAGCTCCACGCCGTGTGGACAAGGTGGATGAAGAGAGATACGACATAGAGGAAAAGTCACCAAGAAC  
ATCACGGAGATTGCGAGATCTGACTCAGAAGATCTTGACCTTCGAGGAAGTTAACGGGCCCACCTCGGGAGAGTGAGG  
ATCTCTGCAGATGCCATGATGCGAGCGCTGCTGGGGCCCGGGCTAAGGAGTCCCTGGACCTCGGGGCCACCTCAAGCAG  
GTGAAGAAGGAGGACACCGAGAAGGAAAACGGGAGGTGGAGACTGGCGGAAGAACATCGATGCACTGAGTGGATGGAG  
GGCCGCAAGAAAAGTTGAGAGCTGA

## RGECO-TnI amino acid sequence

MVDSSRKWNKAGHAVRAIGRLSSPVVSERMYPEDGALKSEIKGLRLKDGGHYAAEVKTTYKAKKPVQLPGAYIVDIKLD  
IVSHNEDYTIVEQCERAEGRHSTGGMDELYKGGTGGSLVKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGRPYE  
AFQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYIKHPADIPDYFKLSPEGFRWERVMNFEDGGIIHVNDSSLQDGFIY  
KVKLRTNFPPDPVMQKKTMWEATRDQLTEEQIAEFKEAFSLFDKDGDTITKELGTVMRSLGQNPTAEELQDMINEV  
DADGDGTDFPEFLTMMARKMNDTDSEEEIREAFRVFDKDGNFYIGAAELRHVMTDLGEKLTDEEVDEMIRVADIQDGQV  
NYEEFVQMMTAKLEMADGSSDAAREPRPAPAPIRRSSNYRAYATEPHAKKSKISASRKLQLKTLLIQIAKQELEREAE  
RRGEKRALSTRCQPLELTGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVR  
ISADAMMQALLGARAKESLDLRAHLKQVKEDTEKENREVGDWWRKNIDALSGMEGRKKKFES.

**Online Figure XI. DNA and amino acid sequence of RGECO-TnI.** Sequence highlighted red is RGECO, blue is human cardiac TnI and black is a XhoI cloning site which corresponds to an additional LE linker sequence in the translated amino acid.

	GFP-TnT	TnT-GFP	GFP-TnI	TnI-GFP	GFP-TnC	TnC-GFP
$\Delta pCa_{50}$	-0.031±0.018	-0.149±0.056	0.028±0.015	-0.279±0.624	0.564±0.269	-0.369±0.125
$\Delta n_H$	0.980±0.691	7.308±3.703	0.505±1.085	<b>-2.158±0.170 **</b>	0.8649±0.598	-0.867±0.912
$\Delta Min\ (sec^{-1})$	0.548±0.219	0.185±0.089	0.235±0.114	<b>3.096±1.105 *</b>	<b>6.551±0.969 ***</b>	<b>5.382±1.874 *</b>
$\Delta Max\ (sec^{-1})$	0.686±0.588	<b>-2.958±0.399 *</b>	-0.036±0.270	0.787±0.457	1.479±0.798	<b>1.439±0.545 *</b>

**Online Table I. Extracted parameters from *in vitro* actin activated acto-myosin S1 ATPase assays performed to investigate myofilament function in the presence of GFP conjugates of the troponin complex.**  $\Delta$  values from paired experimental comparisons for  $pCa_{50}$ ,  $n_H$ , maximum and minimum activity ( $sec^{-1}$ ) with standard error and significance.  $n=5$ , significance values comparing unconjugated with GFP conjugated troponin are  $p<0.001=***$ ,  $p<0.01=**$  and  $p<0.05=*$  using a students t-test.

	RGECO	RGECO-TnT	RGECO-TnI
$K_d$ at 25 °C (nM)	1607	1186	1105
$K_d$ at 37 °C (nM)	860	764	657
Quantum Yield pCa 4.5 ( $\Phi$ )	0.20	0.33	0.3
Quantum Yield pCa 8.5 ( $\Phi$ )	0.06	0.11	0.1
Molar Extinction coefficient pCa 4.5 ( $\epsilon$ (mM <sup>-1</sup> •cm <sup>-1</sup> ) (565 nm))	32.39	34.53	35.87
Molar Extinction coefficient pCa 8.5 ( $\epsilon$ (mM <sup>-1</sup> •cm <sup>-1</sup> ) (565 nm))	5.17	6.64	6.85
Molar Extinction coefficient pCa 4.5 ( $\epsilon$ (mM <sup>-1</sup> •cm <sup>-1</sup> ) (455 nm))	4.16	6.18	6.2
Molar Extinction coefficient pCa 8.5 ( $\epsilon$ (mM <sup>-1</sup> •cm <sup>-1</sup> ) (455 nm))	11.25	14.11	16.36
Brightness pCa 4.5 (mM <sup>-1</sup> •cm <sup>-1</sup> )	6.48	11.30	13.58
Brightness pCa 8.5 (mM <sup>-1</sup> •cm <sup>-1</sup> )	0.31	0.73	1.21
Intensity change ± Ca <sup>2+</sup>	10.18x	10.33x	11.25x

**Online Table II.** Extracted parameters from fluorescence and absorbance spectra and kinetic experiments. Brightness is defined as the product of  $\epsilon$  and  $\Phi$ .

Sensor	n	Time to 50% Ca <sup>2+</sup> Binding (sec)	Time to 50% Ca <sup>2+</sup> Release (sec)
RGECO	108	0.058±0.003	0.308±0.012
RGECO-TnT	55	<b>0.105±0.007 ***</b>	<b>0.282±0.011 **</b>
RGECO-TnI	112	<b>0.097±0.004 ***</b>	<b>0.267±0.006 ***</b>

**Online Table III. Extracted parameters of GPCM Ca<sup>2+</sup> transients transduced with RGECO, RGECO-TnT or RGECO-TnI.** Extracted values from a paired comparison of GPCMs adenovirally transduced with RGECO, RGECO-TnT or RGECO-TnI. n = total cell number from at least 3 separate cell isolations, ± = standard error. Significance values comparing RGECO to RGECO-TnT or RGECO-TnI are p<0.01 = \*\* and p<0.001 = \*\*\*. RGECO-TnT verses RGECO-TnI = ns for all parameters, using a Kruskal Wallis non parametric test.

**A**

Sensor	Mutant	n	Relative RGEKO Peak Intensity	Time to 50% Ca <sup>2+</sup> Binding (sec)	Time to 50% Ca <sup>2+</sup> Release (sec)	Time of Peak (sec)
RGEKO	WT cTnT	94	1.00±0.041	0.066±0.002	0.219±0.006	0.288±0.007
RGEKO	cTnT R92Q	94	0.99±0.045	<b>0.102±0.004 ***</b>	<b>0.247±0.006 **</b>	<b>0.365±0.007 ***</b>
RGEKO	WT cTnI	107	1.00±0.037	0.070±0.002	0.198±0.004	0.281±0.006
RGEKO	cTnI R145G	103	<b>1.60±0.058 ***</b>	<b>0.083±0.002 ***</b>	<b>0.255±0.005 ***</b>	<b>0.345±0.008 ***</b>

**B**

Sensor	Mutant	n	Relative RGEKO Peak Intensity	Time to 50% Ca <sup>2+</sup> Binding (sec)	Time to 50% Ca <sup>2+</sup> Release (sec)	Time of Peak (sec)
RGEKO-TnI	WT cTnT	102	1.00±0.039	0.087±0.003	0.194±0.004	0.333±0.007
RGEKO-TnI	cTnT R92Q	115	<b>1.32±0.053 ***</b>	<b>0.128±0.005 ***</b>	<b>0.247±0.004 ***</b>	<b>0.424±0.008 ***</b>
RGEKO-TnT	WT cTnI	123	1.00±0.030	0.082±0.003	0.202±0.005	0.338±0.008
RGEKO-TnT	cTnI R145G	127	<b>1.16±0.042 **</b>	<b>0.094±0.003 **</b>	<b>0.247±0.005 ***</b>	<b>0.391±0.010 ***</b>

**Online Table IV. Extracted parameters of GPCMs transduced with RGEKO or myofilament localised RGEKO and WT/HCM mutant troponin.** Extracted Ca<sup>2+</sup> transient values from GPCMs adenovirally transduced with RGEKO (A) or RGEKO-TnI/RGEKO-TnT (B) and either WT cTnT, cTnT R92Q, WT cTnI, or cTnI R145G. n = total cell number from at least 3 separate cell isolations, ± = standard error. Significant values comparing either WT cTnT to cTnT R92Q or WT cTnI to cTnI R145G are p<0.001 = \*\*\*, or p<0.01 = \*\* using a Mann Whitney test.